CPHI Korea kicks off on August 25–26, 2026, bringing together global nutritional ingredient brands, OEM manufacturers, and buyers from the Asia-Pacific region to explore new trends in precision nutrition. EXTRABROC®, a stable, high-conversion sulforaphane ingredient, will make its debut at this international event—marking another step in its global expansion following exhibitions in Europe and Shanghai. With four key differentiators—high conversion rates, superior stability, robust evidence, and full regulatory compliance—it breaks free from the industry's cycle of commoditized competition, offering global brands a high-barrier, market-ready sulforaphane solution.

Solving Industry Pain Points: Moving Beyond the "Hot Research, Poor Real-World Application" Dilemma

While the mechanisms behind sulforaphane’s efficacy have been validated by thousands of papers and hundreds of human studies worldwide, the industry has long faced significant shortcomings. Market products often compete solely on glucoraphanin content while ignoring actual conversion rates within the body; efficacy fluctuates due to gut microbiome variability, leading to inconsistent consumer experiences. The core issue is not a lack of research into the ingredient itself, but rather the absence of mature engineering systems in traditional ingredients—preventing the stable translation of laboratory-proven benefits into tangible, effective results for the end consumer.

Functional nutrition has now transitioned from an era of conceptual marketing to one of evidence-based systems. With consumers prioritizing genuine mechanisms and clinical data, global regulations tightening, and AI-driven searches making verifiable scientific evidence a core competitive advantage, ingredients marketed merely on "high content" can no longer meet the demands of industry evolution.

Reimagining Ingredient Logic: Delivering Verifiable Efficacy through Systems Engineering

EXTRABROC® is more than just a single extract; it is a patented functional sulforaphane system comprising three key modules: standardized aqueous seed extract, active myrosinase, and a proprietary stabilization system. Moving beyond superficial competition based on content levels, the product focuses on "Effective Sulforaphane Yield" (ESY) in the human body. By prioritizing actual in-vivo activity as the core standard, it transforms efficacy from a vague concept into a robust capability that is measurable, verifiable, and consistently deliverable. EXTRABROC® aligns with five key industry trends—precise product matching, transparent mechanisms, clinical evidence, verifiable credibility, healthy aging, and systemic nutrition. Backed by robust mechanistic evidence, clinical data, and compliance credentials, it meets the needs for global new product development and regulatory compliance.

Empowering brands for efficient market entry: short cycles, low risk, and strong scientific barriers.

Unlike the industry-standard 12–24 month R&D cycle, EXTRABROC® compresses the time-to-market for new products to just 3–6 months, significantly cutting R&D costs and trial-and-error risks. Supported by comprehensive academic backing, clinical case studies, and a global patent and compliance framework, it helps brands build unique scientific narratives and establish a competitive edge in the market.

Industry White Paper Launching Soon

To help enterprises strategically enter the sulforaphane sector and expand into global markets in compliance with regulations, the EXTRABROC® Commercial White Paper on Stable, High-Conversion Sulforaphane Ingredients* is launching soon. It offers a comprehensive implementation solution for the industry, featuring practical content such as brand launch roadmaps, ESY screening checklists, and guidelines for compliant claims in domestic and international markets.